Polyrizon Ltd. (PLRZ)
NASDAQ: PLRZ
· Real-Time Price · USD
0.00
-0.00 (-100.00%)
At close: May 23, 2025, 3:59 PM
Company Description
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel.
The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithelial tissue.
It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza.
The company was incorporated in 2005 is headquartered in Ra'anana, Israel.
Polyrizon Ltd.
| Country | IL |
| IPO Date | Oct 29, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Tomer Izraeli |
Contact Details
Address: 5 Ha-Tidhar Street Ra'anana, IL | |
| Website | https://www.polyrizon-biotech.com |
Stock Details
| Ticker Symbol | PLRZ |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001893645 |
| CUSIP Number | M79549107 |
| ISIN Number | IL0011814113 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Tomer Izraeli | Founder, Chief Executive Officer & Director |
| Daphna Avital | Chief People Officer |
| Dr. Tidhar Turgeman | Chief Technology Officer |
| Nir Ben Yosef | Chief Financial Officer & Compliance Officer |
| Dr. Eyal S. Ron Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 22, 2025 | 6-K | Filing |
| May 21, 2025 | 6-K | Filing |
| May 19, 2025 | 6-K | Filing |
| May 14, 2025 | 6-K | Filing |
| May 12, 2025 | 424B3 | Filing |
| May 01, 2025 | 6-K | Filing |
| May 01, 2025 | 6-K | Filing |
| Apr 30, 2025 | F-1 | Filing |
| Apr 25, 2025 | 6-K | Filing |
| Apr 17, 2025 | 6-K | Filing |